0001193125-26-134720
SEC filingRevenue was $5.0K Operating Income was -$4.2M Net Income was -$4.2M Eps was $-2.20
GAAP revenue for fiscal 2025 was $5.0k, with no revenue derived from product sales as the company remains fully in preclinical development stages. GAAP operating loss for the period totaled $4.2M, with a corresponding net loss of $4.2M and diluted EPS of -$2.20. Net cash used in operating activities for the year was $2.9M, with changes in operating cash flow primarily driven by reductions in the period's net loss, offset by timing shifts in accounts payable and accrued expenses. Other income in the period was lower year over year due to reduced interest income from lower cash reserve balances, partially offset by a gain from the change in fair value of the company's warrant liability. Stock-based compensation expense was recognized in the period consistent with the company's standard accounting policy, measuring fair value at grant date and recognizing expense over the requisite employee service period using the Black-Scholes option pricing model, consistent with prior years.
Management has concluded that current available capital resources are not sufficient to fund planned operations for at least one year following the issuance of these financial statements. The company will need to pursue additional financing to continue its development activities. Capital expenditures for the year totaled $98k, entirely allocated to equipment purchases for the company's obesity and metabolic disorders program, driving the increase in net cash used in investing activities for the period.
The biggest positive development of the period was the successful completion of two non-GLP preclinical studies of its lead obesity candidate in diet-induced obesity mouse models, which delivered statistically significant, dose-dependent weight loss, favorable body composition changes, reduced liver weight, and improved metabolic and liver function biomarkers. These proof-of-concept results support the company's strategy of advancing the non-hormonal oral obesity candidate, which targets a large and fast-growing market with limited non-hormonal treatment options. The company is focusing all available resources on advancing the obesity program, with near-term priorities including completing preclinical work to support future IND-enabling studies, funded by planned future equity, debt, or collaboration arrangements.